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Axon regeneration: Vaccinating against spinal cord injury
Marie T. Filbin
Myelin is a potent inhibitor of axon regeneration, but
has been viewed as just one of many factors that
prevent regeneration after injury. So it comes as a
surprise that immunization against myelin has been
found to allow extensive axon regeneration after injury,
without apparent autoimmune-induced demyelination.
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The inability of the adult mammalian central nervous
system (CNS) to regenerate after injury has confounded
clinicians and scientists alike for centuries. In contrast to
the adult CNS, young neurons will readily extend axons
and successfully regenerate after injury [1,2]. The sugges-
tion has been that, with development and age, CNS
neurons somehow lose the intrinsic capacity to regrow. It
came then as a pleasant surprise when Aguayo and
colleagues [3,4] showed that with a favorable environment
— provided by grafting peripheral nervous system tissue
into the lesion site — CNS neurons were able to extend
very long axons into the implanted tissue. But growth
stopped, or was very limited, when the regenerating axons
again encountered host tissue. 
These observations implied that something in the adult CNS
environment was actively inhibiting axonal regeneration.
Later work implicated myelin as one important component
of the adult CNS environment that acts to prevent axon
regeneration — but it was thought to be just one of a
number of inhibitory factors. Surprisingly, it has now been
reported [5] that the immunization of an animal against
myelin can permit extensive axon regeneration after injury,
even in the absence of any additional treatment to block
other factors that influence regeneration, and without any
apparent autoimmune-induced demyelination.
As noted by Ramon y Cajal [6] almost a century ago, at a
lesion site in the CNS a scar-like formation appears, which
Cajal speculated physically prevented growth. We now
know that the scar at the lesion site is composed of glial
cells that have undergone both a morphological change —
the extension of interdigitating processes — and a
biochemical change — up-regulation of a number of
chondroitin sulfate proteoglycans [7]. The first of these
transformations poses a physical barrier to regrowth, while
the second presents a non-permissive environment for
regeneration. Undoubtedly, the glial scar can directly
block regeneration, but it takes weeks to be fully formed,
even though the up-regulation of chondroitin sulfate pro-
teoglycans begins within hours to days after injury.
The question, then, is why axons do not start to grow
immediately after injury, before the glial scar has time to
form? The most likely answer is that the delay is a
consequence of a third factor — inhibitors of axonal
regeneration found in myelin [8,9]. About a decade ago, a
number of groups simultaneously demonstrated that
myelin, or white matter in general, was non-permissive for
axonal regeneration. If neurons were cultured on tissue
sections of spinal cord, for example, those neurons that fell
on the gray matter extended long axons, while those that
fell on white matter did not [10–12]. Consistent with this
finding is the observation that, when purified myelin was
used as a substrate, neurons extended very short or no
neurites at all [13–15]. 
The conclusion was that something specific to, or greatly
enriched in, CNS myelin actively prevents regeneration.
In contrast, but consistent with their ability to regenerate
in vivo, myelin does not inhibit axonal regeneration from
young neurons [16]. Indeed, the period during which
young axons can regenerate in vivo is extended if the
onset of myelination is delayed [17]. It appears, then, that
two developmental events occur that result in loss of
regenerative capacity: the environment changes (myelin is
formed) and the intrinsic axonal response to that environ-
ment changes (axonal outgrowth becomes inhibited by
myelin). Injury to the CNS damages not only axons but
also myelin, and the damaged axon is thus prevented from
immediate regeneration by exposure of, most likely, both
secreted and membrane-associated inhibitory components
of myelin. The glial scar then forms and seals the fate of
damaged axons to no regeneration.
So how can we encourage axons to regrow immediately
after injury and continue to do so until they reach their
target? There are two general approaches that could be
taken. One would be to induce the neuron to revert to a
‘young’ state such that an adult environment does not
inhibit it. The second would be to block the myelin
inhibitors of regeneration. A recent study has suggested
that the intrinsic growth capacity of adult CNS axons can
indeed be changed in vivo. Neumann and Woolf [18]
showed that, for dorsal root ganglion neurons that have
both axons that extend into the peripheral nervous system
(PNS) and axons that extend into the CNS, if a lesion is
created in the PNS branch one or two weeks before a
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subsequent lesion of the CNS branch, the CNS axons will
regrow through what is normally a highly non-permissive
environment for those axons. It would seem that the
peripheral-branch-conditioning lesion has changed the
growth capacity of dorsal root ganglion neurons such that
inhibitors in the environment no longer block growth of
the CNS axons. The molecular mechanism responsible for
the change in these neurons remains to be determined.
However, recent studies have shown that, when the
endogenous neuronal cAMP levels are elevated, axonal
growth is no longer inhibited by myelin [19]. It is possible
that the conditioning lesion in some way alters the cAMP
levels in dorsal root ganglion neurons, which then allows
them to grow through myelin [20].
The approach of blocking inhibitory components of
myelin to encourage regeneration has been pioneered in
Schwab’s laboratory. Schwab and Caroni [13] identified an
inhibitory activity enriched in myelin protein fractions of
250 kDa and 35 kDa. A monoclonal antibody raised to the
250 kDa fraction, termed IN-1, was shown to allow axons
to grow, not only on myelin in culture [21] but, more
importantly, in vivo [22,23]. When hybridoma cells
secreting the IN-1 antibody were implanted at the same
time as a spinal cord lesion was created, a number of axons
were shown to grow relatively long distances and, in some
instances, functional recovery occurred. But although
some long-distance growth was achieved, at most only
5–10% of axons regrew, suggesting that myelin is likely to
contain other inhibitors, in addition to IN-1, that
contribute to the lack of regeneration. A novel protein,
termed Nogo, has recently been shown to be recognized
by the IN-1 antibody [24]. When presented to a growing
axon, Nogo induces growth-cone collapse. Another
inhibitory component of myelin is the well-characterized
myelin-associated glycoprotein (MAG). MAG is a very
potent inhibitor of axonal growth in vitro [14,15] and an
inhibitory proteolytic fragment of MAG, released from
damaged myelin [25], is likely to play an important role in
preventing regeneration immediately after injury.
In addition to MAG and Nogo, there are likely to be many
other inhibitors of axon regeneration in myelin. A number
of repulsive guidance cues, which act during development,
have also recently been identified in the adult nervous
system [26–29] and a proteoglycan associated with myelin
has recently been shown to be inhibitory for axonal growth
[30]. The task of individually identifying and neutralizing
all the inhibitors of axonal regeneration in the adult CNS is
thus not as simple or straightforward as at first believed. It
is likely that the effects of these inhibitors are not additive,
and that the presence of any one will effectively inhibit
growth. What is the alternative to blocking each individu-
ally? The answer may be to devise a means to block them
all simultaneously. That is exactly what David and col-
leagues have achieved in their recent study [5].
Previous attempts to encourage regeneration focused,
logically, on treatment after the injury has occurred. What
is different and novel about the approach taken by Huang
et al. [5] is that they ‘vaccinated’ mice against myelin
inhibitors of regeneration before inflicting the injury. Using
a protocol developed by Rodriguez et al. [31] to produce
antibodies that promote remyelination, mice were immu-
nized for three weeks before injury with either isolated
myelin or preparations of spinal cord that were enriched in
myelin but also contained some proteoglycans. When
examined three weeks after spinal cord injury, numerous
axons were seen to have regenerated over long distances in
more than 50% of the immunized mice, while no regenera-
tion was seen in control injected animals (Figure 1).
The distance of regeneration observed by Huang et al. [5]
in the immunized mice was 5–11 mm, comparable to
distances reported by Schwab and colleagues [22,23] after
application of the IN-1 antibody to transected rat spinal
cord. But many more axons regenerated in the myelin-
immunized mice than those treated with IN-1 antibody.
A further difference between the IN-1-antibody-treated
and the myelin-immunized animals is the relative dis-
tance traversed by the regenerating axons. Regeneration
in the myelin-immunized mice was up to about two-
thirds of the entire spinal cord; while axons grew similar
absolute distances in the IN-1-antibody-treated rats, in
this case the regeneration reached only about one-quarter
of spinal cord. Importantly, functional recovery accompa-
nied anatomical regeneration in the immunized mice.
The sera from these myelin-immunized mice also
allowed extensive axonal growth on myelin in culture,
and if the sera was depleted of immunoglobulins, the
effect was lost.
Given that it has been known for more than a decade that
myelin contains inhibitors of regeneration, why was such a
procedure, which in retrospect appears quite simple, not
carried out earlier? Most likely, this was because
immunization of mice with myelin is used to induce exper-
imental allergic encephalophy (EAE), considered the
closest animal model of the human demyelinating disease
multiple sclerosis. Allowing axonal regeneration, but at the
same time inducing multiple sclerosis, would not be a very
appealing treatment. But Huang et al. [5] took advantage of
Rodriguez et al.’s finding [31] that, for induction of EAE,
mice must be immunized with myelin in complete
Freund’s adjuvant; with incomplete Freund’s adjuvant
there was no indication of inflammation or demyelination. 
An additional deterrent to immunization with myelin may
have been the expectation that the antibodies produced
would be unable to penetrate the blood brain barrier to
get to the site of injury in the spinal cord. This concern
appears to be unfounded, as immunostaining showed
that, three days after injury, immunoglobulins are present
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along the myelin tracts up to 5 mm from the injury site.
So the antibodies are obviously reaching their target. 
An outstanding issue is whether the antibodies have to
precede or accompany the regenerating axon along its
entire path, or if they are only needed for the initial stages
of growth, across the lesion site and through the exposed
myelin inhibitors. Work from Silver’s group [32,33] would
suggest the latter. By carefully transplanting isolated adult
neurons into adult spinal tracts without inducing any
damage and no glial scar, Silver and colleagues observed
extensive axonal growth from the transplanted neurons,
through white matter tracts. Under these conditions,
myelin is not damaged and presumably the inhibitors are
not exposed. So the axons are growing on the intact
myelin surface, which to our knowledge contains no
inhibitors. The same situation may occur in the myelin-
immunized mice, in that the antibodies may only be
required to allow the axons to traverse the site of exposed
inhibitors. Once they reach myelin tracts that are undam-
aged, perhaps the axons too grow on the outer surface,
which appears to be permissive for growth.
What happened to the glial scar in these myelin-immu-
nized mice? Because of ‘pinching’ at the original lesion
site, in some mice it would appear that the scar formed
after and around the regenerated axons. This is the
strongest direct evidence presented to date that inhibitors
in myelin prevent regeneration immediately after injury,
and that there is a period of time after injury before the
glial scar and its associated proteoglycans become impedi-
ments to growth. It should be noted, however, that there
are differences between the reaction to injury in rats and
mice. In rats there is a greater tendency for a fluid-filled
cyst to form (cavitation) at the lesion site than there is in
mice. In six of the myelin-immunized mice in which
regeneration did not occur there were cavitations. On the
other hand, perhaps regeneration immediately after
injury in some way limits both cavitation and glial scar
formation. In myelin-immunized mice that did not regen-
erate, perhaps the antibody titer was not high enough and
the cavitations and scars formed because of the absence
of regeneration.
The big question, of course, is whether this vaccination
approach is a valid, potential therapy in humans with
spinal cord injury. Although the mice studied by Huang
et al. [5] showed no sign of demyelination, it would seem
very risky and impractical to immunize the population as a
whole against myelin antigens. The risk of promoting
autoimmune demyelinating disease is just too great.
Instead, rather than use immunization as a prophylactic
treatment, the ideal situation would be to be able to
immunize, with the same beneficial outcome, at the same
Figure 1
Axon regeneration in the spinal cord (a) without
and (b) after immunization against myelin. As
recently reported by Huang et al. [5],
immunization of mice against myelin allows
axon regeneration over long distances; in the
absence of immunization, no regeneration is
seen. Red, myelin inhibitors of regeneration;
green, anti-myelin antibodies; yellow, glial
scar. (See text for details.)
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time as the spinal cord injury occurred. For this to be suc-
cessful, the production of myelin antibodies would have to
be rapid and plentiful. 
We have been surprised by both the ability of axons to
regrow at all after injury and the ability to ‘vaccinate’
against myelin inhibitors [5], so it may not be outlandish
to hope that immunization simultaneously with injury will
allow regeneration. Alternatively, exogenously produced
myelin antibodies can be introduced to the lesion site
along with immunization. The consequent passive immu-
nity might compensate for the interim period required for
endogenous antibody production. What is even more com-
pelling, yet puzzling, is the possibility that these same
myelin antibodies also promote remyelination [31]. To
complement this immunization strategy, treatments that
alter the intrinsic growth capacity of the axon could also be
applied simultaneously. Finally, as always with these
regeneration studies, once we have encouraged the
damaged axons to regrow we have to redirect them back to
their original destinations, a problem that may be greater
for long-distance rather than short-distance regeneration.
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